For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.mycme.com/courses/personalized-antidepressant-choices-for-better-outcomes-in-mdd-10266 Summary Emphasizing a measurement-based, patient-centered model, this is an enduring podcast/webcast designed for psychiatrists who seek to refine their approach to managing major depressive disorder (MDD). Despite an expanding array of pharmacologic options, many patients continue to experience side effects and residual symptoms that undermine adherence and long-term recovery. Led by Drs. Gregory Mattingly and Gerald Maguire, this activity equips clinicians with evidence-based strategies to compare the nuanced risk–benefit profiles of antidepressants and apply them to individualized treatment plans. This podcast was recorded and is being used with permission of the presenters. Learning Objectives Assess the risk–benefit profiles of available antidepressants, including their impact on residual symptoms, to optimize treatment decisions for patients with MDD Implement personalized, measurement-based treatment strategies for patients with MDD to address residual symptoms, promote adherence, and improve outcomes This activity is accredited for CME/CE Credit This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians. The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.75 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at
[email protected] . Summary of Individual Disclosures Please review faculty and planner disclosures here. Disclosure of Commercial Support This educational activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
